A Stuursma1, C M G van Driel2, N J Wessels3, G H de Bock4, M J E Mourits5. 1. Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: a.stuursma@umcg.nl. 2. Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
OBJECTIVES: To reduce the risk of ovarian cancer, women with BRCA1/2 mutations are advised to undergo risk-reducing salpingo-oophorectomy (RRSO) at a premenopausal age. Premenopausal RRSO results in acute menopause and is associated with various menopausal symptoms. This study investigates the severity and duration of subjective menopausal symptoms after premenopausal RRSO and associated factors. METHODS: We included 199 women who had undergone RRSO before age 52 in this cross-sectional study. The Menopause Rating Scale (MRS) was used to measure the level of psychological, somato-vegetative and urogenital symptoms (no/little, mild, moderate, or severe). Uni- and multivariate logistic regressions were performed to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for having moderate or severe symptoms as compared to having no or mild symptoms. Duration of symptoms was investigated by calculating the time since RRSO. RESULTS: Sixty-nine percent (137/199) of the included women reported moderate or severe symptoms on the MRS, a mean of 7.9 years after RRSO. Fifty-seven percent (94/137) of these women reported severe urogenital symptoms, and about one-quarter reported severe psychological and/or somato-vegetative symptoms. Only psychological symptoms tended to improve over time (>=10 years). A personal history of breast cancer was independently associated with having moderate or severe menopausal symptoms (OR = 3.4; 95%CI = 1.6-7.1). CONCLUSIONS: The majority of women report moderate or severe menopausal symptoms, even 10 years after surgical menopause, and breast cancer survivors especially. To improve quality of life, follow-up care after RRSO should focus on these symptoms and be accessible for many years after RRSO.
OBJECTIVES: To reduce the risk of ovarian cancer, women with BRCA1/2 mutations are advised to undergo risk-reducing salpingo-oophorectomy (RRSO) at a premenopausal age. Premenopausal RRSO results in acute menopause and is associated with various menopausal symptoms. This study investigates the severity and duration of subjective menopausal symptoms after premenopausal RRSO and associated factors. METHODS: We included 199 women who had undergone RRSO before age 52 in this cross-sectional study. The Menopause Rating Scale (MRS) was used to measure the level of psychological, somato-vegetative and urogenital symptoms (no/little, mild, moderate, or severe). Uni- and multivariate logistic regressions were performed to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for having moderate or severe symptoms as compared to having no or mild symptoms. Duration of symptoms was investigated by calculating the time since RRSO. RESULTS: Sixty-nine percent (137/199) of the included women reported moderate or severe symptoms on the MRS, a mean of 7.9 years after RRSO. Fifty-seven percent (94/137) of these women reported severe urogenital symptoms, and about one-quarter reported severe psychological and/or somato-vegetative symptoms. Only psychological symptoms tended to improve over time (>=10 years). A personal history of breast cancer was independently associated with having moderate or severe menopausal symptoms (OR = 3.4; 95%CI = 1.6-7.1). CONCLUSIONS: The majority of women report moderate or severe menopausal symptoms, even 10 years after surgical menopause, and breast cancer survivors especially. To improve quality of life, follow-up care after RRSO should focus on these symptoms and be accessible for many years after RRSO.
Authors: Phuong L Mai; Helen Q Huang; Lari B Wenzel; Paul K Han; Richard P Moser; Gustavo C Rodriguez; John Boggess; Thomas J Rutherford; David E Cohn; Noah D Kauff; Kelly-Anne Phillips; Kelly Wilkinson; Robert M Wenham; Chad Hamilton; Matthew A Powell; Joan L Walker; Mark H Greene; Martee L Hensley Journal: Gynecol Oncol Date: 2019-11-21 Impact factor: 5.482
Authors: Lara Terra; Maartje J Hooning; Bernadette A M Heemskerk-Gerritsen; Marc van Beurden; Jeanine E Roeters van Lennep; Helena C van Doorn; Joanne A de Hullu; Constantijne Mom; Eleonora B L van Dorst; Marian J E Mourits; Brigitte F M Slangen; Katja N Gaarenstroom; M Carola Zillikens; Tim Leiner; Lizet van der Kolk; Margriet Collee; Marijke Wevers; Margreet G E M Ausems; Klaartje van Engelen; Lieke Pv Berger; Christi J van Asperen; Encarna B Gomez-Garcia; Irma van de Beek; Matti A Rookus; Michael Hauptmann; Eveline M Bleiker; Sanne B Schagen; Neil K Aaronson; Angela H E M Maas; Flora E van Leeuwen Journal: JMIR Res Protoc Date: 2021-01-22